Intercept Pharmaceuticals (NASDAQ: ICPT) recently received a number of ratings updates from brokerages and research firms:

  • 7/13/2017 – Intercept Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/11/2017 – Intercept Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $136.00 price target on the stock. According to Zacks, “Intercept received a boost with the approval of Ocaliva in 2016 and the initial uptake of the same has been encouraging. The drug’s sale is expected to pick up further in 2017. The PBC market holds strong potential.  We are also encouraged by Intercept’s efforts to develop the drug for additional indications. A potential label expansion of the drug will further boost sales. The company does not expect much contribution from international markets in 2017 and most of it will be loaded in the second half as it works to obtain reimbursements in various European countries. However, expenses are expected to continue to rise as the company invests in commercial activities related to Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline.  Moreover, the company’s share underperformed the industry in the last one year.”
  • 7/10/2017 – Intercept Pharmaceuticals is now covered by analysts at Jefferies Group LLC. They set a “buy” rating and a $275.00 price target on the stock.
  • 7/5/2017 – Intercept Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/23/2017 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $231.00 price target on the stock.
  • 6/23/2017 – Intercept Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/13/2017 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $231.00 price target on the stock.
  • 6/12/2017 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cowen and Company. They wrote, “We hosted a group investor lunch recently with ICPT management.””
  • 6/3/2017 – Intercept Pharmaceuticals was given a new $201.00 price target on by analysts at Credit Suisse Group. They now have a “buy” rating on the stock.
  • 6/2/2017 – Intercept Pharmaceuticals was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 5/26/2017 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $231.00 price target on the stock.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) opened at 124.50 on Wednesday. The stock has a 50 day moving average of $122.25 and a 200-day moving average of $116.97. Intercept Pharmaceuticals, Inc. has a 52 week low of $96.63 and a 52 week high of $177.93. The firm’s market cap is $3.11 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($3.61) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($4.27) by $0.66. The company had revenue of $21 million during the quarter, compared to analysts’ expectations of $15.88 million. Intercept Pharmaceuticals had a negative net margin of 825.58% and a negative return on equity of 116.30%. Intercept Pharmaceuticals’s quarterly revenue was up 4566.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($5.17) earnings per share. Analysts expect that Intercept Pharmaceuticals, Inc. will post ($14.40) earnings per share for the current year.

In related news, CMO David Shapiro sold 1,117 shares of the business’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $112.18, for a total value of $125,305.06. Following the completion of the transaction, the chief marketing officer now owns 46,582 shares of the company’s stock, valued at $5,225,568.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Sandip Kapadia sold 1,431 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $121.59, for a total value of $173,995.29. Following the completion of the transaction, the chief financial officer now directly owns 20,569 shares of the company’s stock, valued at approximately $2,500,984.71. The disclosure for this sale can be found here. In the last three months, insiders sold 47,023 shares of company stock valued at $6,064,412. 4.50% of the stock is currently owned by company insiders.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.